SequelSEC

Biohaven Ltd. BHVN

Pharmaceutical Preparations · CIK 0001935979 · Fiscal year ends 1231

Revenue
Unavailable
Fiscal year ended 2026-06-30
Operating income
-$567.44M
Fiscal year ended 2026-06-30
Free cash flow
-$511.87M
Fiscal year ended 2026-06-30

Biohaven Ltd. (BHVN) reported net income of -$586.84M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Biohaven Ltd.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Biohaven Ltd. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
RevenueUnavailable
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$567.44M
Net income-$586.84M
Research & development$467.76M
Weighted-average diluted sharesUnavailable
Pretax income-$585.61M
Income tax expense$1.24M
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$99.69M
Selling & marketingUnavailable

Balance

Biohaven Ltd. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$238.03M
Total assets$370.74M
Current assets$296.56M
Total liabilities$358.52M
Current liabilities$62.66M
Total equity incl. NCI$12.22M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
Goodwill$1.39M
Long-term debtUnavailable
Accounts payable$12.11M

Cash flow

Biohaven Ltd. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$511.40M
Capital expenditures$475.00K
Investing cash flow$211.26M
Financing cash flow$371.73M
Net change in cash$71.63M
Stock-based compensation$85.94M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$10.32M

Derived

Biohaven Ltd. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$511.87M
Gross marginUnavailable
Operating marginUnavailable
FCF marginUnavailable
SBC / revenueUnavailable
Current ratio4.73x
Revenue YoY growthUnavailable
Net marginUnavailable
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BHVN in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-10View SEC filing
10-Q · Filed 2026-05-04View SEC filing
10-K · Filed 2026-03-02View SEC filing
10-Q · Filed 2025-11-10View SEC filing
10-Q · Filed 2025-08-11View SEC filing
10-Q · Filed 2025-05-12View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.